Lexeo Therapeutics (LXEO) Other Working Capital Changes (2022 - 2026)

Lexeo Therapeutics has reported Other Working Capital Changes for 5 years, with the latest figure at -$402000.0 in Q1 2026.

• Quarterly Other Working Capital Changes fell 12.61% year-over-year to -$402000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.5 million (down 11.83% YoY) and the FY2025 annual result came in at -$1.5 million, down 11.98% from the prior year.
• Other Working Capital Changes retreated to -$402000.0 in Q1 2026 per LXEO's latest filing, from -$394000.0 in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $2.2 million in Q2 2025 and troughed at -$2.1 million in Q3 2025.
• A 4-year average of $294076.9 and a median of $201000.0 in 2024 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes plunged 72.83% in 2023, then jumped 30.31% in 2024.
• Over 5 years, Other Working Capital Changes stood at -$184000.0 in 2022, then slumped by 72.83% to -$318000.0 in 2023, then retreated by 13.84% to -$362000.0 in 2024, then declined by 8.84% to -$394000.0 in 2025, then decreased by 2.03% to -$402000.0 in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered -$402000.0, -$394000.0, and -$381000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.